Furthermore, these medications contribute to improved metabolic health and may lower the risk of cardiovascular diseases
Improvements in visceral adiposity exceeded those observed in the comparator group receiving a sodium-glucose cotransporter 2 (SGLT2) inhibitor
The positivity assumption of the HDPS was checked using a Love plot
Black circle added to the green indicates that these synthetic agonists have been slightly modified
Los medicamentos GLP-1 aprobados por la FDA, como semaglutida (Ozempic, Wegovy) y liraglutida (Victoza, Saxenda), producen aumentos farmacolgicos sostenidos en la actividad del receptor de GLP-1, resultando en reducciones de hemoglobina A1c de 1.0-1.5% y prdida de peso de 10-15% o ms
Per CDC patient resources, treatment goals should be realistic (510% weight loss produces significant health benefits)